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Introduction {#sec001}
============

Human herpesvirus-6A (HHV-6A) and HHV-6B (HHV-6A/B) are two distinct betaherpesviruses with different epidemiological and biological characteristics \[[@ppat.1008496.ref001]\]. HHV-6B is a ubiquitous virus that infects nearly 100% of world population and is the etiological agent of roseola infantum, an infantile febrile illness characterized by high fever and skin rash \[[@ppat.1008496.ref002]\]. HHV-6B is also a concern in hematopoietic stem cell and solid organ transplant recipients with frequent reactivation and medical complications \[[@ppat.1008496.ref003]\]. Pathological and epidemiological data on HHV-6A remain scarce.

The viral genomes of HHV-6A/B are composed of a unique segment of approximately 143 kilo base pair (kbp) flanked at both extremities with identical and directly repeated (DR) termini of approximately 9 kbp each \[[@ppat.1008496.ref004], [@ppat.1008496.ref005]\]. Each DR contains two TTAGGG telomeric repeat arrays that are required for the integration of the HHV-6A/B genome into human chromosomes \[[@ppat.1008496.ref006]\] and reviewed in \[[@ppat.1008496.ref007], [@ppat.1008496.ref008]\]. The number of TTAGGG telomeric repeats within each DR ranges from 15 to 180 in clinical isolates \[[@ppat.1008496.ref009]--[@ppat.1008496.ref012]\]. HHV-6A/B integration can occur in several distinct chromosomes, and it invariably takes place in the telomeric/sub-telomeric regions of chromosomes \[[@ppat.1008496.ref013]--[@ppat.1008496.ref016]\]. When integration occurs in a gamete, the viral genome can be inherited resulting in individuals carrying a copy of the viral genome in every cell, a condition called inherited chromosomally-integrated HHV-6A/B (iciHHV-6A/B) \[[@ppat.1008496.ref017]\]. Approximately 1% of the world population have this condition (reviewed in \[[@ppat.1008496.ref008]\]). Chromosomally-integrated HHV-6A/B are not silent and can spontaneously express viral genes with the U90 and U100 generally being the most abundant in various tissues \[[@ppat.1008496.ref018], [@ppat.1008496.ref019]\]. Expression of such viral genes is correlated with a greater antibody response in iciHHV-6A/B subjects relative to age and sex matched controls \[[@ppat.1008496.ref019]\]. The consequences of having iciHHV-6A/B are not well defined but a recent study suggests that these individuals are at greater risks of developing angina pectoris \[[@ppat.1008496.ref020]\].

Mammalian chromosome extremities consist in 5--50 kbp of (TTAGGG)~n~ repeats followed by a single-stranded 3'-overhang of 200 +/-75 TTAGGG nucleotides \[[@ppat.1008496.ref021]\]. With each cell division, the extremities of the chromosomes are not completely replicated due to the end replication problem of the cellular DNA polymerase \[[@ppat.1008496.ref022]\]. As a consequence, the telomeres shorten with every cell division until they reach a minimal length threshold, which triggers DNA damage activation via the ATR (ataxia telangiectasia and Rad3 related) or the ATM (ataxia telangiectasia mutated) pathway, ultimately leading to senescence or cell death (reviewed in \[[@ppat.1008496.ref023], [@ppat.1008496.ref024]\]). In the absence of telomere elongation processes, such as expression of telomerase or activation of the alternative lengthening of telomere (ALT) pathway, somatic cells are limited in their number of replication cycles.

To prevent activation of DNA damage recognition pathways, telomeres are protected by a six-member protein complex, termed shelterin \[[@ppat.1008496.ref023]\]. The shelterin components TRF1 and TRF2 form homodimers that bind the double-strand TTAGGG repeats and recruit the rest of the complex (TPP1, RAP1, TIN2 and POT1) to chromosome ends \[[@ppat.1008496.ref025]--[@ppat.1008496.ref027]\]. The shelterin complex folds telomeric DNA into a secondary structure called the T-Loop, preventing the recognition of the telomere extremity as a double-strand break (DSB) \[[@ppat.1008496.ref028]\]. TRF2 represses activation of the ATM pathway \[[@ppat.1008496.ref029]\] and plays an essential role in end-to-end chromosome fusions mediated by the non-homologous end-joining (NHEJ) pathway \[[@ppat.1008496.ref030], [@ppat.1008496.ref031]\]. POT1 binds to the single-strand section of the telomeres and protects the telomeres against activation of the ATR pathway \[[@ppat.1008496.ref030], [@ppat.1008496.ref032]--[@ppat.1008496.ref034]\].

Certain viruses are reported to affect telomeres in different ways. For example, infection by herpes simplex virus type 1 (HSV-1) alters telomere integrity through transcriptional activation of the telomeric noncoding RNA (TERRA), loss of total telomeric DNA, selective degradation of TPP1, reduction of telomere-bound shelterin and accumulation of DNA damage at telomeres \[[@ppat.1008496.ref035]\]. Telomere remodeling is presumed to be required for ICP8-nucleation to form a pre-replication compartment that stimulates HSV-1 replication \[[@ppat.1008496.ref035]\]. The Epstein-Barr virus (EBV) LMP1 protein was reported to downmodulate the expression of TRF1, TRF2 and POT1 shelterin genes resulting in telomere dysfunction, progression of complex chromosomal rearrangements, and multinuclearity \[[@ppat.1008496.ref036], [@ppat.1008496.ref037]\]. The impact of HHV-6A/B infection on telomere biology is currently unknown. Considering that telomeres are the preferred sites for HHV-6A/B integration, it is important to understand the dynamic processes occurring during the early phases of infection to gain insights into the integration mechanisms. In the present study, we analyzed the impact of HHV-6A/B infections on shelterin complex homeostasis and show for the first time that the shelterin components are recruited to the viral DNA during infection and play a critical role in HHV-6A/B chromosomal integration.

Materials and methods {#sec002}
=====================

Cell lines and viruses {#sec003}
----------------------

U2OS cells (American Type culture collection (ATCC), Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM, Corning Cellgro, Manassas, VA, USA) supplemented with 10% Nu serum (Corning Cellgro), non-essential amino acids (Corning Cellgro), HEPES, sodium pyruvate (Multicell Wisent Inc., St-Bruno, Québec, Canada) and plasmocin 5 μg/ml (InvivoGen, San Diego, CA, USA). Molt-3 (ATCC, CRL-1552), HSB-2 (ATCC, CCL-120.1), Sup-T1 (ATCC, CRL-1942), all human T lymphoblastic cell lines, were cultured in RPMI-1640 (Corning Cellgro) supplemented with 10% fetal bovine serum (FBS), HEPES and plasmocin 5 μg/ml. J-Jhan (RRID:CVCL_1H08) cells infected with wild type (WT) HHV-6A-BAC, HHV-6A mutants lacking telomeric repeats (TMR) termed ΔTMR and ΔimpTMR \[[@ppat.1008496.ref006]\] or HHV-6A BAC WT\#2 (containing a red fluorescent protein downstream of the U11 gene) were cultured in RPMI-1640 supplemented with 10% FBS. HHV-6B (Z29 strain) and HHV-6A (U1102 strain) were propagated and titered on Molt-3 and HSB-2 cells respectively, as previously described \[[@ppat.1008496.ref038]\].

Plasmids {#sec004}
--------

IE2 expression vectors (WT and Δ1290--1500) were previously described \[[@ppat.1008496.ref039]\]. pLPC-MYC-hTRF1 (Addgene plasmid \#64164) \[[@ppat.1008496.ref040]\], pLPC-NMYC TRF2 (Addgene plasmid \# 16066) \[[@ppat.1008496.ref041]\] and pSXneo 135(T2AG3) (Addgene plasmid\#12402) \[[@ppat.1008496.ref042]\] were gifts from Titia de Lange and obtained through Addgene. The generation of pLKO human shTRF2 was previously described \[[@ppat.1008496.ref043]\]. The shTRF2 coding sequence was cloned into the Tet-pLKO-puro vector (Addgene \#21915). The Tet-pLKO-puro vector was a gift from Dmitri Wiederschain \[[@ppat.1008496.ref044]\].

Western blots {#sec005}
-------------

Cells were resuspended in Laemmli buffer and boiled for 5 minutes. Samples were loaded and electrophoresed through a SDS-polyacrylamide gel. Samples were transferred onto PVDF membranes and processed for western blot using rabbit anti-TRF2 (Novus Biologicals), mouse anti-tubulin (Sigma-Aldrich) and rabbit anti-p85 antibodies (Abcam). Peroxidase-labeled goat anti-rabbit IgG and peroxidase-labeled goat anti-mouse IgG were used as secondary antibodies. The Bio-Rad Clarity ECL reagent was used for detection.

IF-FISH and microscopy {#sec006}
----------------------

Immunofluorescence (IF) combined with fluorescence *in situ* hybridization (FISH) (IF-FISH) was performed as previously described \[[@ppat.1008496.ref045]\]. U2OS cells were seeded at 5 x 10^4^ cells per well in 6-well plates over coverslips, cultured 24 hours and infected with HHV-6A or HHV-6B at a multiplicity of infection (MOI) of 5 for 4 hours. Cells were then washed with PBS and cultured in media for a set period of time. Cells were fixed with 2% paraformaldehyde. Molt-3 and HSB-2 cells were infected at a MOI of 1 and cultured for a set period of time before being deposited on a 10-well microscope slide, dried and fixed in acetone at -20°C for 10 minutes. The following primary antibody were used: mouse-α-IE2-Alexa-594 \[[@ppat.1008496.ref046]\], mouse-α-p41 (NIH AIDS Reagent Program), rabbit-α-TRF2 (NB100-56694, Novus Biologicals), and mouse-α-Myc (clone 9E10). Secondary antibodies used were goat-α-rabbit-Alexa-488, goat-α-mouse-Alexa-488 and goat-α-mouse-Alexa-594 (Life Technologies). FISH was performed using a PNA probe specific to the telomeric sequence (CCCTAA)~3~ (TelC-Cy5, PNA BIO). Slides were observed at 40X and 63X using a spinning disc confocal microscope (Leica DMI6000B) and analyzed with the Volocity 5.4 software.

To compare TRF2 expression in uninfected and HHV-6A-infected cells, cells were dually stained with HHV-6A IE2 protein and TRF2. The relative TRF2 fluorescence in IE2- and IE2+ individual cell was then determined using the ImageJ software.

For colocalization, acquisitions were deconvoluted using the Volocity 5.4 software and Point Spread Function (PSF) respective to the objective and the immersion medium to remove the out-of-focus information from the acquisitions. 3D images were reconstructed using the same software to visualize colocalization. To quantify colocalization of IE2 with telomeres, TRF1, TRF2 or p41, Image J software with JACoP plugin was used. Briefly, after setting up thresholds, total fluorescence of IE2 colocalizing with the fluorescence of telomeres, TRF1, TRF2 or p41was given by Mander's colocalization coefficient (MCC) and reported in percentage were a coefficient of 1 represent 100% of colocalization and 0 equal no colocalization.

Telomere restriction fragment (TRF) analysis {#sec007}
--------------------------------------------

DNA from uninfected, HHV-6A/B-infected cells and HHV-6A BAC (WT and ΔTMR)-infected cells was isolated using QIAamp DNA blood isolation kits as per the manufacturer's recommendations. Five μg of DNA were digested overnight with RsaI and HinfI followed by electrophoresis through agarose gel and southern blot hybridization. The telomeric DNA probe was obtained following digestion of the pSXneo135(T2AG3) vector with EcoRI and NotI, gel purification of the 820 bp fragment and ^32^P-labeling by nick translation. The HHV-6A U94 probe was obtained by digesting the pMalC2-U94A vector \[[@ppat.1008496.ref047]\] with BamHI and HindIII, gel purification of the 1476 bp fragment and ^32^P-labeling by nick translation. After hybridization and washes, the membranes were exposed to X-ray films.

ChIP and dot blot {#sec008}
-----------------

The experiments were made using the Pierce Magnetic ChIP Kit (Thermo Scientific) according to the manufacturer's instructions with a few modifications. Equal quantities of HSB-2 and Molt-3 cells were used for all samples (4 x 10^6^ cells/sample). Cross-linking lasted 10 minutes at RT. Two μl of diluted MNase (1:10) were added to each sample for MNase digestion. Sonication was made with a Branson Sonifier 450, with an Output Control set at 1. Each sample was sonicated with five pulses of 20 seconds, each pulse followed by a 20 seconds incubation on ice. After sonication, an aliquot was saved for normalization purpose (input). Before immunoprecipitation, samples were incubated with magnetic beads alone for one hour at 4°C before discarding the beads. The immunoprecipitation was performed using 4 μg of normal rabbit IgG (negative control), 10 μl of anti-PolII antibodies (positive control) and 4 μg of rabbit anti-TRF2 antibody (NB100-56694, Novus Biologicals) with an overnight incubation at 4°C. Protein A agarose beads were added for 1h at 4˚C followed by three washes. The DNA was eluted in 50 μl of DNA column elution solution.

Eluted DNA was analyzed by quantitative PCR (qPCR) for GAPDH promoter sequences using reagents and conditions provided by the manufacturers (Pierce Magnetic ChIP Kit, Thermo Scientific) or analyzed by dot blot hybridization using a telomeric probe or HHV-6A probe (DR6). The input was analyzed using an Alu probe. For dot blot hybridization, DNA was first denatured for 10 minutes at room temperature in 0.25 N NaOH and 0.5 M NaCl. Samples were then serially diluted in 0.1 X SSC and 0.125 N NaOH, on ice, loaded onto nylon membrane, neutralized in 0.5 M NaCl and 0.5 M Tris-HCl pH 7.5 and crosslinked using UV irradiation. Membranes were pre-incubated in Perfecthyb Plus hybridization buffer (Sigma-Aldrich) for 2h at 68˚C before addition of 1 x 10^6^ CPM/ml of ^32^P-labeled probes. Hybridization was carried out for 16h at 68˚C. Membrane was washed twice with 2X SSC-1% SDS, twice with 1X SSC-1% SDS and once with 0.5X SSC-1% SDS at 68˚C, for 15 minutes each. Membrane was then exposed to X-ray films at -80˚C. Hybridization signals were measured by densitometry.

Cloning and purification of MBP-TRF2 {#sec009}
------------------------------------

The TRF2 coding sequence was excised from pLPC-NMYC TRF2 vector using with BamHI and XhoI and cloned in frame with the Maltose-Binding Protein (MBP) coding sequence of the pMAL-C2 vector (New England Biolabs) using BamHI and SalI enzymes. MBP and MBP-TRF2 proteins were expressed in BL21 DE3 RIL bacteria and purified by affinity chromatography, as described \[[@ppat.1008496.ref047]\].

Electrophoretic mobility shift assay (EMSA) {#sec010}
-------------------------------------------

EMSA was performed essentially as described \[[@ppat.1008496.ref047]\]. In brief, recombinant proteins (MBP and MBP-TRF2) were incubated with 1 pmole of double-stranded (ds) non-telomeric or telomeric labeled probes in 20 μl of the following reaction buffer: 20 mM Hepes-KOH pH 7.9, 150 mM KCl, 1 mM MgCl~2~, 0.1 mM EDTA, 0.5 mM DTT, 5% glycerol and 0.1 mg/ml BSA. For competition experiments, 10--1000 fold excess unlabeled double-stranded (ds) non-telo or telomeric probes were included in the reaction buffer. After a 30 minutes incubation at room temperature, 2 μl of loading dye were added and the samples were electrophoresed through a non-denaturing 5% acrylamide:bis (29:1) gel. After migration, the gels were dried and exposed to X-ray films at -80˚C.

Detection of TRF2 binding to HHV-6A telomeric sequence {#sec011}
------------------------------------------------------

The wells of a 96-well ELISA plate were coated with 0.6 pmoles of MBP or MBP-TRF2 proteins by overnight incubation at 4˚C in pH 9.0 carbonate buffer. After rinsing, 1% BSA was added to block non-specific sites. Twenty-five nanograms of HaeIII-digested digoxigenin-labeled HHV-6A DNA (HaeIII cuts the viral genome 289 times) (approximately 0.16 pmoles) in EMSA reaction buffer were added. For competition experiments, 2.5 or 5.0 pmoles of non-telomeric or telomeric dsDNA were added 15 minutes prior to the addition of HHV-6A DNA. The plate was incubated for 2h at room temperature (RT). After 3 washes with TBS-0.1% Tween-20 (TBS-T), peroxidase-labeled mouse anti-DIG antibodies were added to each well for 1h at RT. After 3 additional TBS-T washes, TMB substrate was added and the reaction allowed to develop for 15 minutes before addition of 50 μl of 2N sulfuric acid. Absorbance was measured at 450 nm.

HHV-6A/B integration assay {#sec012}
--------------------------

HHV-6A/B integration frequency in U2OS cells was determined by droplet digital PCR (ddPCR) as previously described \[[@ppat.1008496.ref018]\]. In brief, cells were infected with either HHV-6A or HHV-6B for 5 h at 37°C and then washed 3× with PBS to remove unadsorbed virions prior to the addition of fresh culture medium. Upon confluence, cells were passaged into the well of a 6-well plate for a few days and further expanded into a 25-cm^2^ flask for a month until analyzed by ddPCR. ddPCR uses TaqMan chemistry but instead of using a standard curve to estimate copy numbers, it partitions the reaction into thousands of droplets, which are each read as positive or negative for DNA template allowing absolute quantification of DNA copies \[[@ppat.1008496.ref048], [@ppat.1008496.ref049]\]. HHV-6A/B copy numbers were determined. The HHV-6A/B chromosomal integration frequencies were estimated assuming a single integrated HHV-6/cell and calculated with the following formula: (\# *of HHV*6 *copies* ÷ (\# *of RPP*30 *copies* ÷ 2 *copies per cell*)) × 100. Such a procedure and protocol proved equivalent to estimation of ciHHV-6 frequency using single-cell cloning procedures \[[@ppat.1008496.ref018]\].

Statistical analysis {#sec013}
--------------------

TRF2 expression levels were compared using unpaired student t-test with Welch's correction. Binding of MBP-TRF2 to HHV-6A DNA and HHV-6A/B integration frequency were determined using the Mann-Whitney test. Colocalization of IE2 WT and Δ1290--1500 IE2 mutant with telomeres was determined using a t-test. The % of HHV-6A infected cells in shCtrl and shTRF2 +/- Dox was compared using a one-way ANOVA with Tukeys multiple comparisons test. A p value \<0.05 was considered significant.

Results {#sec014}
=======

Telomeric sequence accumulation during HHV-6A infection {#sec015}
-------------------------------------------------------

Telomeres protect chromosomes from the loss of genetic information due to end replication problem and the shelterin complex prevents induction of a DNA damage response (DDR). Interestingly, each end of the HHV-6A/B genome also contains telomeric repeats arrays that vary in number between 15 and 180 \[[@ppat.1008496.ref009]--[@ppat.1008496.ref012]\] ([Fig 1A](#ppat.1008496.g001){ref-type="fig"}). During infection, viral replication compartments (VRC) can be visualized by staining cells with antibodies against the DNA polymerase processivity factor p41, encoded by the *U27* gene, that associates with the viral DNA during replication ([Fig 1B](#ppat.1008496.g001){ref-type="fig"}). The majority (92% ± 7%) of HHV-6A immediate-early 2 (IE2) protein colocalizes with the p41 protein and is used in subsequent experiments as marker of VRC \[[@ppat.1008496.ref050]\]. Using immunofluorescence combined with fluorescent *in situ* hybridization (IF-FISH), we first studied the accumulation of telomeric sequences during active HHV-6A infection. Hybridization of mock-infected HSB-2 cells with a telomeric probe resulted in the detection of many discrete punctate telomeric signals corresponding to terminal chromosomal telomeric repeats ([Fig 1B and 1C](#ppat.1008496.g001){ref-type="fig"}). In contrast, a mixture of small and large telomeric signals were observed during HHV-6A infection. At late stages of infection when viral genome replication is abundant, very intense telomeric signals were detected. These telomeric signals correspond to replicating virus genomes as they localize with the p41 ([Fig 1B](#ppat.1008496.g001){ref-type="fig"}) and IE2 protein ([Fig 1C](#ppat.1008496.g001){ref-type="fig"}). Similar accumulation of telomere signal resembling VRC were observed in HHV-6B-infected cells ([Fig 1D](#ppat.1008496.g001){ref-type="fig"}). Considering that our IE2 antibody is specific for HHV-6A, staining for HHV-6B IE2 was not possible \[[@ppat.1008496.ref046], [@ppat.1008496.ref051]\]. Next, the increase in telomeric signals observed by IF-FISH was confirmed by dot blot hybridization. DNA from uninfected and HHV-6A/B infected cells was hybridized with a telomeric probe to estimate overall telomeric repeats. Hybridization with an Alu probe was used for normalization. HHV-6A/B infection resulted in a 2.5x to 2.9x increase in the total number of telomeric signals relative to uninfected cells ([Fig 1E](#ppat.1008496.g001){ref-type="fig"}). To determine the origin (cellular or viral) of the increased telomeric signals, DNA from uninfected and HHV-6A/B infected cells was analyzed by terminal restriction fragment (TRF) analysis and southern blot hybridization with a telomeric probe. As shown in [Fig 1F](#ppat.1008496.g001){ref-type="fig"}, HSB-2 and Molt-3 uninfected cells displayed telomeric signal with lengths ≥4kbp. In addition to the cellular telomeric signal observed, HHV-6A/B-infected cells displayed abundant signals that were smaller in size (\<2kbp) and much stronger in intensity, likely representing viral telomeric repeats. To confirm the viral origin of these telomeric repeats, J-Jhan cells were infected with HHV-6A U1102 (control), WT HHV-6A-BACs or HHV-6A ΔTMR BAC that lacks the viral telomeric sequences \[[@ppat.1008496.ref006]\]. In J-Jhan cells, low molecular weight telomeric signals were detected in HHV-6A and WT HHV-6A BACs but were absent in cells infected with HHV-6A ΔTMR BAC confirming the viral origin of telomeric signal. Infection was confirmed by hybridizing the membrane with a probe corresponding to the HHV-6A *U94* gene, expected to hybridize to a 964 bp viral DNA fragment.

![Accumulation of viral telomeric signals during HHV-6A infection.\
A) Schematic representation of the HHV-6A/B genome. The unique (U) region of the HHV-6A/B genome (143--145 kbp) is flanked by two direct repeat sequences (8--10 kbp) referred to as DR~L~ and DR~R~. The DRs contain perfect (TTAGGG)~n~ and imperfect (het (TTAGGG)~n~) telomeric sequences. The genome is not drawn to scale. B) HSB-2 cells were mock treated or infected with HHV-6A. After 5 days, cells were processed for IF-FISH to detect HHV-6A IE2 protein (red), p41 (green) and telomeres (cyan) to appreciate HHV-6A VRC. Nuclei are outlined by the circular dashed lines. C) Mock or HHV-6A-infected HSB-2 cells were processed for IF-FISH to detect IE2 and telomeric signals patterns in presence of HHV-6A. Low and high magnifications of cells are presented. Nuclei are outlined by circular dashed lines. D) Molt-3 cells were infected with HHV-6B for 4 days and hybridized with a telomeric probe (cyan) with nuclei stained with DAPI. Nuclei are outlined by circular dashed lines. E) HSB-2 and Molt-3 cells were respectively infected with HHV-6A and HHV-6B. After 5 days, total DNA was isolated and analyzed by dot blot hybridization using Alu and telomeric probes. The relative increase in telomeric signals was determined by densitometry after normalization to uninfected controls. F) HSB-2 and Molt-3 cells were respectively infected with HHV-6A and HHV-6B. J-Jhan cells were infected with HHV-6A U1102, WT HHV-6A BACs or HHV-6A BAC ΔTMR. After 4 days, DNA was extracted, digested with HinfI and RsaI and processed for southern blot hybridization using ^32^P-labeled telomeric and U94 probes. G) J-Jhan cells were infected with HHV-6A U1102, WT recombinant HHV-6A BACs, HHV-6A mutant lacking the imperfect telomeric repeats (ΔimpTMR) or HHV-6A mutant lacking all telomeric repeats (ΔTMR). After 5 days of infection, cells were processed for IF-FISH to detect HHV-6A IE2 protein and telomeres (cyan). Some infected cells expressing IE2 are identified by arrows. Nuclei were stained with DAPI and outlined by dashed lines.](ppat.1008496.g001){#ppat.1008496.g001}

The accumulation of telomeric sequences was also confirmed by IF-FISH using J-Jhan cells infected with HHV-6A recombinant BACs. As with HSB-2 cells, mock-infected J-Jhan showed typical telomeric staining ([Fig 1G](#ppat.1008496.g001){ref-type="fig"}, first row). J-Jhan cells productively infected with HHV-6A demonstrated large telomeric signals that colocalized with the viral IE2 protein (second row). To demonstrate that the increased telomeric signals observed originates from viral DNA, we made use of HHV-6A mutants lacking either only the imperfect telomeric repeats (ΔimpTMR) or all telomeric repeats (ΔTMR) \[[@ppat.1008496.ref006]\]. Infection with the ΔimpTMR mutant still resulted in a strong and patchy telomeric signals ([Fig 1G](#ppat.1008496.g001){ref-type="fig"}, third row). In contrast, telomeric hybridization signals in ΔTMR-infected J-Jhan cells were similar to those observed in uninfected J-Jhan cells ([Fig 1G](#ppat.1008496.g001){ref-type="fig"} last row), confirming that telomeric sequences within the viral genome were responsible for the increased telomeric signals observed.

Binding of TRF2 to viral telomeric sequences {#sec016}
--------------------------------------------

Telomeres are protected by the shelterin complex of which TRF1 and TRF2 bind directly to TTAGGG repeats; however, it remains unknown if shelterin proteins bind to viral telomeric sequences in the context of the HHV-6A/B genomes. To study TRF2 binding to viral TMRs, a recombinant MBP-TRF2 protein was generated. To validate that MBP-TRF2 was functional and capable of binding telomeric DNA, we performed EMSA. MBP-TRF2 efficiently bound dsDNA with telomeric sequences causing a mobility shift ([Fig 2A](#ppat.1008496.g002){ref-type="fig"}). MBP alone did not bind the telomeric probe. The specificity of MBP-TRF2 binding was confirmed by competition with excess unlabeled telomeric and non-telomeric oligonucleotides. Excess (100--1000 fold) of unlabeled telomeric oligonucleotides efficiently competed with labeled telomeric probes. No such competition was observed with excess non-telomeric oligonucleotides. Lastly, no binding of MBP or MBP-TRF2 was observed using non-telomeric labeled probes ([Fig 2B](#ppat.1008496.g002){ref-type="fig"}).

![Binding of TRF2 to HHV-6A viral DNA.\
A) Recombinant MBP or MBP-TRF2 were incubated with ^32^P-labeled telomeric dsDNA and binding was assessed by EMSA. Excess of unlabeled telomeric and non-telomeric dsDNA were added as competitors. Samples were migrated on non-denaturing acrylamide gel, dried and exposed to X-ray films. B) Recombinant MBP or MBP-TRF2 were incubated with ^32^P-labeled non-telomeric dsDNA and binding was assessed by EMSA. C) Recombinant MBP and MBP-TRF2 were coated to the wells of a 96 well-plate and incubated with HaeIII digested DIG-labeled HHV-6A DNA (25 ng/condition) in the presence or absence of competitors. After washing, bound DNA was quantified by adding peroxidase-labeled anti-DIG antibodies and substrate. Results are expressed as mean absorbance +SD of triplicate values. Experiment is representative of two additional experiments. \* P\<0.001.](ppat.1008496.g002){#ppat.1008496.g002}

After validation of the specific binding to telomere sequences of the recombinant MBP-TRF2 protein, we next determined if MBP-TRF2 could bind to HHV-6A TMR DNA. To study this, DIG-labeled HHV-6A-BAC DNA was digested with the HaeIII enzyme that cuts on both sides of the viral TMR and more than 250 times in the viral genome. MBP and MBP-TRF2 coated wells were incubated with the mixtures of DNA fragments (25 ng) and DNA binding was measured using anti-DIG antibodies. MBP did not bind viral DNA, in contrast to MBP-TRF2 that efficiently bound viral DNA ([Fig 2C](#ppat.1008496.g002){ref-type="fig"}). Specificity of MBP-TRF2 binding to viral TMR was confirmed through competition with unlabeled ds oligonucleotides containing telomeric motifs (Telo comp) but not by ds oligonucleotides with non-telomeric motifs (non Telo comp). Our *in vitro* binding assay revealed that the recombinant MBP-TRF2 efficiently binds to viral DNA at TMRs.

To provide additional support that TRF2 binding occurs during infection, we performed TRF2 ChIP in HHV-6A and HHV-6B productively-infected cells. Uninfected cells were used as negative controls. To discriminate between telomeres of cellular and viral origin, the TRF2 immunoprecipitated DNA was hybridized with the DR6 probe, corresponding to regions adjacent (1.5kbp) to the TMR in the virus genome (refer to [Fig 3A](#ppat.1008496.g003){ref-type="fig"}). As positive control, binding of PolII to the GAPDH promoter was analyzed by qPCR. As shown in [Fig 3B](#ppat.1008496.g003){ref-type="fig"}, GAPDH promoter sequences were highly enriched following anti-PolII precipitation. Next, DNA bound to TRF2 was immunoprecipitated (IP) using anti-TRF2 antibodies and the corresponding DNA analyzed by dot blot hybridization. Hybridization with a telomeric probe indicates that TRF2 efficiently bound telomeres in both uninfected and HHV-6A- and HHV-6B-infected cells ([Fig 3C--3F](#ppat.1008496.g003){ref-type="fig"}). Compared to uninfected cells, a stronger telomeric signal was observed in infected cells. TRF2 also precipitated DNA that hybridized preferentially (10-fold) with the DR6 probe in HHV-6A-infected cells ([Fig 3C and 3D](#ppat.1008496.g003){ref-type="fig"}). As negative control, DNA was immunoprecipitated with an irrelevant mouse anti-IgG. Similar results were obtained for HHV-6B ([Fig 3E and 3F](#ppat.1008496.g003){ref-type="fig"}). In summary, these assays provide evidence that TRF2 binds the telomeric motifs present in HHV-6A/B DNA during productive HHV-6A/B infections.

![Binding of TRF2 to viral DNA during HHV-6A/B infection.\
A) Schematic representation of the HHV-6A/B genome. The DR6 probe used for hybridization is shown in red. Uninfected and HHV-6A-infected HSB-2 cells (B-D) or uninfected and HHV-6B-infectd Molt-3 cells (E-F) were analyzed for TRF2 binding to viral DNA using ChIP. The input was hybridized with Alu probe to assess quantity of starting material. Anti-IgG (negative control), anti-PolII (positive control) or TRF2 antibodies were used for immunoprecipitation. B) QPCR detection of GAPDH DNA following ChIP. Results are expressed as fold increase over control IgG. C and E) Eluted DNA was hybridized with ^32^P-labeled Alu, telomeric (TTAGGG)~3~ or HHV-6A (DR6) probes. After hybridization the membranes were washed and exposed to X-ray films. D and F) Densitometric analysis of relative binding of TRF2 to telomeric and viral DNA. Results of one experiment representative of three are presented and are expressed as signal after normalization to input.](ppat.1008496.g003){#ppat.1008496.g003}

HHV-6A and shelterin during infection of U2OS cells {#sec017}
---------------------------------------------------

Considering that HHV-6A/B integration invariably occurs in telomeres of infected cells, we surmise that shelterin proteins likely play a role in viral integration. As most T cells are lytically infected and subsequently killed, HHV-6A/B integration does not occur frequently in these cells. We therefore studied the fate of shelterin proteins in HHV-6A/B-infected U2OS cells that are semi-permissive to infection and used to study viral integration \[[@ppat.1008496.ref018]\]. After 24h, 48h and 72h post-infection, individual cells were analyzed for TRF2 expression. Infected cells were distinguished from uninfected bystander cells using the HHV-6A specific anti-IE2 antibody ([Fig 4A](#ppat.1008496.g004){ref-type="fig"}). Depending on the time of infection, between 38% (24 h post infection) and up to 60% (72h post-infection) of IE2 colocalized with TRF2. TRF2 fluorescence was quantified using ImageJ software. The results obtained indicate that starting at 24h post-HHV-6A infection, TRF2 expression gradually increases as infection progresses. TRF2 is expressed at significantly higher levels in infected cells relative to bystanders or uninfected cells (p ≤ 0.02) ([Fig 4B](#ppat.1008496.g004){ref-type="fig"}). No significant difference in TRF2 expression was detected between bystander and mock-treated cells. In summary, these results indicate that expression of TRF2 increases during HHV-6A-infection of U2OS cells.

![TRF2 expression in HHV-6A-infected U2OS cells.\
U2OS cells were infected with HHV-6A and analyzed for TRF2 and IE2 expression at 24h, 48h and 72h post-infection by dual color immunofluorescence. A) Representative immunofluorescence of TRF2 and IE2 expression in bystander and IE2 expressing cells at 24, 48h and 72h post infection. B) Mean relative TRF2 expression ± SD in uninfected (blue), IE2- (green-uninfected bystander) or IE2+ (red-infected) cells at 24h, 48h and 72h post infection. Each symbol represents the relative TRF2 expression from a single nucleus.](ppat.1008496.g004){#ppat.1008496.g004}

Colocalization of TRF2 with viral DNA during infection of U2OS cells was studied next. Although permissive to entry and expression of viral genes, viral DNA replication is observed only in a minority of HHV-6A/B infected U2OS cells. As shown in [Fig 5A](#ppat.1008496.g005){ref-type="fig"} (middle row), some cells display large patchy IE2 staining similar to what is observed during productive infection of T cells ([Fig 1B and 1C](#ppat.1008496.g001){ref-type="fig"}) and likely representing VRC. Such IE2 patches overlapped with diffuse TRF2 and telomeric signals. Uninfected cells (top row) only showed punctate and sharp TRF2 and telomeric signals. In the majority of cells, (bottom row), the presence of diffuse telomeric signals and "patchy" IE2 was not observed. In these cells, IE2 is present as small punctate structures. On average, 47%±25% of punctate IE2 colocalized with TRF2 and telomeres.

![Colocalization of shelterin complex proteins and HHV-6A IE2 protein at VRC and cellular telomeres.\
A) U2OS cells were mock-infected or infected with HHV-6A for 48h after which cells were processed for IF-FISH. Telomeres were labeled in magenta, TRF2 in green and IE2 in red. The panels in the middle row show images of cells with IE2 patches overlapping with large, diffuse TRF2 and telomeric staining (rectangles). The panels in the third row represent infected cells with punctate IE2 pattern colocalizing with TRF2 and telomeres (dashed squares). The colocalization of IE2, TRF2 and telomeres are shown in both 2D and 3D images. B) Uninfected and HHV-6A-infected U2OS cells were transfected with an empty vector, a myc-tagged-TRF1 expression vector. Forty-eight hours later cells were processed for IF-FISH. TRF1 was labeled in green and IE2 in red. Nuclei were stained with DAPI. Images on the far right show 2D colocalization of TRF1 with IE2.](ppat.1008496.g005){#ppat.1008496.g005}

We next investigated whether TRF1, another shelterin protein binding to TTAGGG repeats, colocalizes with HHV-6A DNA during infection. U2OS were transfected with a myc-tagged-TRF1 expression vector, infected with HHV-6A and analyzed by IF-FISH. We used an expression vector to express a tagged version of TRF1 since available antibodies against TRF1 were not specific. As shown in [Fig 5B](#ppat.1008496.g005){ref-type="fig"}, in addition to its typical punctate pattern, TRF1 also was distributed in diffuse patches that colocalized with IE2/VRC (78% ±20%)

Results from Figs [4](#ppat.1008496.g004){ref-type="fig"} and [5](#ppat.1008496.g005){ref-type="fig"} indicated that a significant proportion of IE2 colocalizes with TRF1, TRF2 and telomeres during infection. We next determined whether ectopically-expressed IE2 ([Fig 6A](#ppat.1008496.g006){ref-type="fig"}) would also localize with telomeres in the absence of other viral proteins and viral DNA. U2OS were transfected with an empty vector or an IE2 expression vector and cells were analyzed by IF-FISH 48h later. In the absence of viral DNA, IE2 always distributes itself with a punctate nuclear distribution. In average, 58%±30% of IE2 foci colocalized with cellular telomeres ([Fig 6B and 6C](#ppat.1008496.g006){ref-type="fig"}). Considering that IE2 possesses a DNA-binding domain (DBD), its telomeric localization was studied next. The IE2 mutant (Δ1290--1500) lacking the DBD localized with telomeres with equal efficiency (57%±22%) as WT IE2, indicating that the DBD is dispensable for IE2 localization with telomeres ([Fig 6B and 6C](#ppat.1008496.g006){ref-type="fig"}). There were no statistically significant differences (p\>0.05) in the telomere colocalization frequencies between IE2 expressed during infection and ectopically expressed IE2. Lastly and as further control, we analyzed the nuclear distribution and colocalization of ectopically expressed p41 viral protein with TRF2. As shown in [Fig 6D](#ppat.1008496.g006){ref-type="fig"}, ectopically-expressed p41 exhibited mostly a perinuclear distribution that did not colocalize with cellular telomeres.

![A) A stick diagram of the IE2 protein with various domains identified is presented. B) Colocalization of HHV-6A IE2 protein with telomeres in the absence of viral DNA. U2OS cells were transfected with an empty vector, with IE2 expression vector or with IE2 Δ1290--1500 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. Telomeres were labeled in cyan and IE2 in red. Nuclei are outlined by dashed lines. Examples of IE2 colocalizing with telomeres are presented in a 3D view (white arrows). C) The graph represents the mean ± SD % of WT IE2 and Δ1290--1500 IE2 localizing with telomeres. D) Lack of colocalization between HHV-6A p41 and telomeres in uninfected cells. U2OS cells were transfected with an empty vector or with a p41 expression vector. Forty-eight hours later cells were processed for dual color immunofluorescence. TRF2 was labeled green, p41 in red and nuclei outlined by a dashed line.](ppat.1008496.g006){#ppat.1008496.g006}

TRF2 is essential for efficient localization of IE2 at cellular telomeres {#sec018}
-------------------------------------------------------------------------

Considering that HHV-6A IE2 colocalizes with TRF2 at cellular telomeres and with TRF2 at VRC, we hypothesized that TRF2 might influence IE2 localization. We generated a U2OS cell line carrying a doxycycline (Dox)-inducible shRNA targeting TRF2 mRNA. Incubation of cells with Dox for 7 days resulted in TRF2 knockdown ([Fig 7A and 7B](#ppat.1008496.g007){ref-type="fig"}). In both control and TRF2 knockdown cells, the IE2 nuclear distribution, whether as punctate foci or patches, was similar ([Fig 7B](#ppat.1008496.g007){ref-type="fig"}). The percentage of HHV-6A-infected cells was also equivalent in the presence or absence of TRF2 ([Fig 7C](#ppat.1008496.g007){ref-type="fig"}). However, when the localization of IE2 at cellular telomeres was estimated, we observed a significant reduction of IE2 at cellular telomeres in the absence of TRF2 ([Fig 7D](#ppat.1008496.g007){ref-type="fig"}). In shCtrl cells (+Dox), 65±23% of IE2 foci were found localizing with telomeres while in shTRF2 (+Dox) treated cells, 13±6% of IE2 foci were found with telomeres (p\<0.0001). Confocal IF-FISH revealed the lack of localization of IE2 with telomeres in the absence of TRF2 ([Fig 7E](#ppat.1008496.g007){ref-type="fig"}).

![TRF2 is required for IE2 localization with telomeres.\
U2OS cells were transduced with a lentiviral vector coding for a Dox inducible control shRNA (shCtrl) or a shRNA against TRF2 (shTRF2) and selected with puromycin +/- Dox for a week. A) Western blot analysis of TRF2 expression one week post selection. Membranes were also probed with anti-tubulin antibodies to show the input material loaded. B) One week post selection, +Dox cells were infected with HHV-6A for 48h and processed for IFA using anti-TRF2 (green) and anti-IE2 (red). Cells with IE2 in punctate form and cells with large patchy IE2, likely to represent VRC, are shown. Nuclei are outlined by dashed lines. C) The percentage of HHV-6A infected cells (from B) was estimated after counting a minimum of 700 cells and scoring the IE2^+^ ones. Results are expressed as mean %IE2^+^ cells ± SD. D) Mean percentage ± SD of IE2 localizing with telomeres in the presence (shCtrl +Dox) and absence (shTRF2 +Dox) of TRF2. Each dot represents the % of IE2 foci localizing with telomeres in one nucleus. \*\*\*\*p\<0.0001. E) IF-FISH confocal images of shCtrl (+Dox) and shTRF2 (+Dox) cells analyzed for TRF2 (green), IE2 (red) and telomeres (cyan). Nuclei are outlined by dashed circles. Examples of IE2 localizing with telomeres (top row) or not found with telomeres (bottom row) are highlighted by the dashed polygons.](ppat.1008496.g007){#ppat.1008496.g007}

Importance of TRF2 for efficient HHV-6A/B chromosomal integration {#sec019}
-----------------------------------------------------------------

Considering that TRF2 colocalizes and interacts with viral DNA during HHV-6A/B infections and that IE2 localization at cellular telomeres is influenced by TRF2, we next determined whether TRF2 knockdown would affect HHV-6A/B chromosomal integration. U2OS were transduced with lentiviral vectors constitutively expressing a scrambled shRNA (shCtrl) or shTRF2. After a week of puromycin selection, TRF2 expression and efficiency of knockdown was monitored by western blot analysis. Compared to the shCtrl, TRF2 expression was significantly reduced by the shTRF2 ([Fig 8A](#ppat.1008496.g008){ref-type="fig"}). Control and TRF2 knockdown cells were then infected with HHV-6A or HHV-6B and infections allowed to proceed for a month, after which cells were analyzed by ddPCR to assess relative HHV-6A/B integration frequency, as previously described \[[@ppat.1008496.ref018]\]. Integration frequency of HHV-6A and HHV-6B was reduced by more than 75% (p\<0.05) in TRF2 knockdown cells compared to the shCtrl control ([Fig 8B](#ppat.1008496.g008){ref-type="fig"}), suggesting that TRF2's presence is required for efficient HHV-6A/B chromosomal integration.

![TRF2 knockdown affect HHV-6A/B chromosomal integration.\
A) U2OS cells were transduced with lentiviral vectors expressing a scrambles shRNA (shCtrl) or a shTRF2. After a week of selection, cells were monitored for TRF2 expression by western blot. B) After a week of selection, shCtrl and shTRF2 treated cells were infected with HHV-6A or HHV-6B. After 30 days, DNA was isolated and the relative frequency of integration, relative to shCtrl set at 100%, estimated by ddPCR. \*p\<0.05.](ppat.1008496.g008){#ppat.1008496.g008}

Discussion {#sec020}
==========

Telomeres serve to protect chromosomes from the loss of genetic information. The ends of each chromosome contain several hundreds, even thousands, of tandemly repeated TTAGGG hexamers. Each time a cell divides approximately 150 nucleotides are lost due to the end replication problem \[[@ppat.1008496.ref052]\]. When telomeres get short, these are extended either by the telomerase enzyme complex \[[@ppat.1008496.ref053]\] or alternative lengthening mechanisms \[[@ppat.1008496.ref054]\]. On the other hand, when telomeres get excessively long, proteins such as TZAP, can trim the excess telomeres \[[@ppat.1008496.ref045]\]. Mechanisms sensing the length of telomeres are therefore present in cells to control telomere length. In the present study, we report that during HHV-6A/B infection, the number of TTAGGG repeats per cell increases 2.5 to 2.9 fold. The increase in telomeric sequences originates from replication of the viral genomes that contain between 15 and 180 TTAGGG repeats at each viral extremity \[[@ppat.1008496.ref009]--[@ppat.1008496.ref012]\]. An HHV-6A mutant lacking these telomeric sequences did not show this phenotype.

Chromosome telomeres are consistently bound by shelterin proteins that serve to protect the linear chromosome end from inappropriate repair through DDR \[[@ppat.1008496.ref023]\]. Three shelterin proteins, TRF1, TRF2 and POT1 recognize and bind specifically to the TTAGGG motif \[[@ppat.1008496.ref026], [@ppat.1008496.ref032], [@ppat.1008496.ref033]\]. Shelterin protein binding to DNA of viruses other than HHV-6A/B has been reported previously. Binding of TRF2, TRF1 and Rap1 to EBV *oriP*, that contains three TTAGGGTTA motifs, was reported to modulate EBV DNA replication. TRF2 also interacts with EBNA1, an EBV protein essential for episomal maintenance and replication \[[@ppat.1008496.ref055]\]. While TRF2 and Rap1 promote the replication at *oriP*, TRF1 inhibits it \[[@ppat.1008496.ref055]--[@ppat.1008496.ref057]\]. TRF2, together with Kaposi sarcoma-associated herpesvirus (KSHV) LANA protein bind to the latent origin of replication. Such region does not contain the TTAGGG motif and binding to this region of the viral DNA likely involves a yet to be identified protein \[[@ppat.1008496.ref057]\]. Unlike EBV, the expression of a dominant negative TRF2 does not affect KSHV DNA replication. Whether the presence of telomeric repeats within the HHV-6A/B viral genome would initiate the binding of shelterin proteins was unknown. Our results indicate that during infection, TRF1 and TRF2 localize at viral replication compartments. Using ChIP, we could demonstrate that TRF2 physically associates with HHV-6A/B viral DNA during infection. Furthermore, using recombinant TRF2 and HHV-6A BAC viral DNA, we could show that TRF2 binds directly to viral DNA TMR in the absence of other viral or cellular proteins.

Joining TRF2 at viral replication compartments are the p41 and IE2 viral proteins. p41 is expected to localize with VRC being a DNA polymerase accessory factor. In contrast, the functions of IE2 are only partially known. IE2 is a large nuclear protein (\~1500 amino acids) that behaves as a promiscuous transactivator in gene reporter assays \[[@ppat.1008496.ref039], [@ppat.1008496.ref050]\]. We have previously reported that truncation of the C-terminus abolishes IE2's transactivating potential \[[@ppat.1008496.ref039]\]. Recently, the crystal structure of the IE2 C-terminus revealed that it contains dimerization, DNA-binding and transcription factor binding domains explaining the importance of this region for IE2's transactivation functions \[[@ppat.1008496.ref058]\]. The IE2 C-terminus core structure resembles those of the gammaherpesvirus factors EBNA1 of EBV and LANA of KSHV \[[@ppat.1008496.ref058]\], involved in binding to viral DNA \[[@ppat.1008496.ref059], [@ppat.1008496.ref060]\]. Although IE2 localizes at VRC during infection, whether it binds viral DNA *per se* remains to be demonstrated. However, considering that IE2 localizes at VRC in cells infected with a mutant lacking telomeric repeats (HHV-6A ΔTMR), suggests that IE2 recruitment at VRC is independent of viral telomeric DNA sequences. Furthermore, considering that in the absence of viral DNA, IE2 localizes at cellular telomeres, suggest a potential affinity of IE2 for shelterin complex proteins. Deletion of the IE2 DNA binding domain had no impact on IE2 localization with telomeres, further strengthens the hypothesis the IE2 interacts with proteins found near or associated with telomeres. In support for an IE2-shelterin interaction is the observation that TRF2 knockdown greatly reduces the number of IE2 foci localizing with telomeres. Validation of a physical interaction between IE2 and TRF2 or other telomeric proteins is complicated by our difficulty in immunoprecipitating the IE2 protein. To our knowledge, this is the first report identifying an HHV-6A/B protein localizing at cellular telomeres. Previous work from our laboratory identified IE2 as a Ubc9-interacting protein \[[@ppat.1008496.ref061]\]. Considering that TRF2 can be sumoylated \[[@ppat.1008496.ref062]\] and that Ubc9 is an E2 SUMO conjugating enzyme, it is conceivable that by localizing at telomere, IE2 through its interaction with Ubc9, may influence TRF2 SUMOylation. Knowing that SUMOylated TRF2 is prone to degradation \[[@ppat.1008496.ref062]\], IE2 may therefore regulate TRF2 levels at chromosomal ends to facilitate integration and/or at VRC to free viral DNA from TRF2.

During infection, many viruses provoke a DNA damage response, either because their unprotected genome is recognized as damaged DNA or because of viral proteins triggering a damage signal. While several viruses have ways to evade the DDR pathways, some have developed strategies to make use of the cellular DNA repair proteins to their advantage. Cellular DNA repair proteins have been observed in VRC in various cases and can be helpful or even necessary for completion of the infection \[[@ppat.1008496.ref063]\]. During EBV infection, the proteins involved in the ATM pathway checkpoint and HR repair are found in replication compartments \[[@ppat.1008496.ref064]\]. The use of the DDR machinery by EBV likely increases the possibility of molecular events, stimulating the damage signals causing instability and promoting carcinogenic transformations. Whether viruses can use the DDR proteins in chromosomal integration is controversial, but some studies have suggested it \[[@ppat.1008496.ref063]\]. One example is the Adeno-associated virus (AAV) that uses the cellular NHEJ mechanism for its site-specific integration \[[@ppat.1008496.ref065]\]. HHV-6A/B chromosomal integration is not fully understood but it appears probable that these viruses integrate by HR between the virus' TMRs and the cellular telomeres. The integration occurs solely in telomeres and it has been shown that the telomeric sequences within the HHV-6A genome are essential for efficient integration into chromosomes \[[@ppat.1008496.ref006]\]. Furthermore, the integrated virus has been sequenced and its orientation and missing sections are compatible with an integration by HR between the viral TMR and the telomere \[[@ppat.1008496.ref013], [@ppat.1008496.ref066]--[@ppat.1008496.ref068]\]. The functions of TRF2 binding to HHV-6A/B viral DNA were studied in the context of HHV-6A/B integration. Our results indicate that knockdown of TRF2 impairs the ability of HHV-6A/B to integrate the host chromosomes without affecting the initial phases of infection. At least two non-mutually hypotheses can explain this result. First, TRF2 is known to protect telomeres from a DDR \[[@ppat.1008496.ref069]\]. By binding to the viral TMR, TRF2 may play a similar role by shielding the end of the viral genome from DDR. Second, TRF2 has been shown to participate in HR \[[@ppat.1008496.ref070], [@ppat.1008496.ref071]\]. We therefore surmise that the presence of TRF2 at viral DNA favors chromosomal integration by facilitating HR events between the host telomeres and viral telomeric sequences.

Our studies have focused mostly on TRF2. However, our results indicate that during infection, TRF1 also localizes with VRC. This is not unexpected considering that TRF1, alike TRF2, binds with high affinity to double-stranded DNA containing TTAGGG repeats \[[@ppat.1008496.ref026]\]. Considering that both TRF1 and TRF2 are docking sites for other shelterin proteins \[[@ppat.1008496.ref072]\], it is expected that Rap1, TIN2 and TPP1 are likely to be recruited at VRC during infection. Furthermore, considering a similar role for TRF1 and TRF2 in maintenance of telomere stability, we speculate that knockdown of TRF1 would affect HHV-6A/B integration alike our TRF2 knockdown experiments.

Our work has unraveled the potential importance of the TRF2 during infection and integration. However, our studies are not without limitations. First, the fact that TRF2 null cell are non-viable \[[@ppat.1008496.ref029]\] prevents us from conducting chromosomal integration studies in the complete absence of TRF2. Considering that the integration assay lasts a month, our results likely reflect 30 days survival of cells expressing minimal amounts of TRF2 and containing integrated HHV-6A/B. At this point it therefore cannot be excluded with certainty that integration of HHV-6A/B in the absence of TRF2 can occur. Another limitation of our study is the reliance on immortalized cells to study integration processes. Considering that immortalized cells have telomere elongation mechanisms not typically observed in most primary cells, results from the use of primary cells could differ from those presented in the current study. Unfortunately, many of our protocols require prolonged culture periods, preventing us from using primary cells. Lastly, although our results suggest that shelterin proteins, such as TRF2, likely play a role in facilitating HHV-6A/B integration, the data provided does not prove it. Additional studies addressing the precise integration mechanism are needed before such a conclusion can be reached.

In summary, our studies indicate that during HHV-6A/B infection, the number of telomeric repeats increases significantly, as a result of the replicating viral DNA that contains many TMRs. In the presence of such abundant viral TMRs, TRF2 is recruited to VRCs where it colocalizes with the viral IE2 protein. Reciprocally, the IE2 protein efficiently localizes at cellular telomeres in the presence of TRF2. Lastly, knockdown of TRF2 negatively affected viral integration into host telomeres, highlighting potential new roles for TRF2, and likely IE2, during HHV-6A/B infection and integration.
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Dear Dr. Flamand,

Thank you very much for submitting your manuscript \"Recruitment of TRF2 at viral telomeres prevents DNA-damage response and facilitates human herpesvirus 6A/B chromosomal integration\" (PPATHOGENS-D-19-01517) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Three reviewers have provided comments on this new submission of a previously reviewed manuscript. The two original reviewers acknowledged the considerable strides the authors have made in addressing issues raised in the initial review. Nonetheless, they have numerous questions and concerns, many of which relate to the description of the work. In addition, a third reviewer has raised a number of issues that need to be addressed.

I think this is important and worthwhile work, and I do not want the perfect to be the enemy of the good. While the work was criticized for its descriptive nature, if descriptive work is done well, it can provide a solid foundation for subsequent mechanistic studies. I am thus willing to forego the mechanistic studies requested by a reviewer.

The current paper does not go far enough in acknowledging the boundaries of robust interpretation available based on the data provided. A Results paragraph that begins, "Limitations of our study include, ..." would improve the paper. The claim that the shelterin complex plays a role (\"facilitates\") in integration is plausible, but the data provided do not prove it.

The reviewers have identified numerous specific items for which the description, display, or interpretation need attention. Upon inspection, I agree with their comments.

I will look forward to seeing a revised version of the paper that addresses those concerns.

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: An interesting paper addressing HHV-6A/B chromosomal integration. Overall well written. It describes a significant increase in telomeric repeats upon HHV-6A/B replication and a colocalization of IE2 with the cellular telomeres. Conversely, cellular telomere binding proteins bind to viral telomeric repeats. Specifically, TRF2 is suggested to be important for replication and integration of the virus.

The concept of herpesviruses interfering with telomeric function is not a novel one, but understanding how HHV-6A/B does this may be of particularly interest given the ability of these viruses to integrate in the telomere region. The paper is predominantly descriptive. It would have been interesting to focus more on the mechanisms of how HHV-6A or HHV-6B integration occurs.

Reviewer \#2: Flamand et al. begins to address the fascinating mechanism of HHV-6A/B telomere integration and the potential involvement of the shelterin complex protein TRF2. Several lines of evidence support TRF2 interaction with HHV-6A/B viral TMRs (IF-FISH, in vitro binding assay, ChIP) which is paired with an overall increase in telomere signal and TRF2 expression. Importantly, the second iteration of this manuscript begins to suggest a functional outcome of TRF2 depletion during viral integration.

Overall, the manuscript is well written and is of high importance to the HHV-6A/B and general herpes field. Comments are directed toward the clarity/resolution of immunofluorescence data and refinement of conclusions in regard to the ddPCR based "HHV-6A/B integration assay."

Reviewer \#3: The manuscript by Gilbert-Gerard et al. addresses interesting questions related to the role of mammalian telomeric and telomere-related sequences that are present at the termini of the genomes of human herpesviruses 6A and 6B (HHV-6A and HHV-6B), viruses whose genomes can integrate into telomeres of human chromosomes. In this work, the authors found that, as might be expected in cells containing thousands of viral genomes, telomeric abundance increases in infected cells. In addition, the enhanced telomeric signals colocalize with nuclear regions that contain the viral IE2 and P41 proteins, suggesting that these domains correspond to virus replication compartments (VRC). As demonstrated for other herpesviruses, VRC are sites where coordinated transcription, genome replication, and capsid assembly and filling occur in close proximity. Shelterin components localize to VRC and the shelterin protein TRF2 binds to the viral telomeric repeats. Knockdown of TRF2 in induces a DNA damage response that localizes to VRC. The authors suggest that, in addition to the role the shelterin complex plays in preventing induction of DNA damage responses localized to VRC, it also contributes to the ability of the virus to integrate into host chromosomes.

Studies of how highly prevalent viruses interact with machinery responsible for maintaining the integrity of host chromosomes are of interest and importance. The important observations here are the association of shelterin components with virus replication compartments, and demonstrating that knockdown of TRF2 in induces a DNA damage response that localizes to VRC. The conclusion that this plays a role in chromosomal integration, as opposed to survival of cells in which integration has occurred, is less robust.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: 1. It is argued that TRF2 is not required for IE2 localization at viral replication compartment. These experiments are based on a system with Dox-inducible shRNA, but unfortunately, these experiments lack certain controls of the Dox system. Dox may have a number of off-target effects, which are not controlled for in the experiments (e.g. Ahler et al., Doxycycline alters metabolism and proliferation of human cell lines. PLoS One, 2013).

To appreciate the data in fig.8, a control for shTRF2 is missing; that is, a control which is also treated with Dox.

In fig.8D it is argued that 53BP1 is located in foci in the absence of TRF2. It may be correct, but Fig.8A shows that TRF2 is indeed expressed in the presence of Dox, and since there is no staining for TRF2 in Fig. 8D it is difficult to draw this conclusion.

Also, there seems to be an inconsistency between the expression level of TRF2+Dox in Fig.8A and the level found by immunofluorescence in Fig.8B, which raises the issue of the kinetics of TRF2 expression during Dox treatment.

2\. In the title the authors claim that recruitment of TRF2 prevents DNA-damage response, but the investigation of this response is rather superficial and does not provide much inside into what is actually going on. It is speculated in the discussion that integration occurs through HR. Nevertheless, the authors restrict their investigation to only examine the expression of a phosphorylated 53BP1 by immunofluorescence, although 53BP1 in association with RIF1 (not examined) are known for promoting NHEJ repair. Indeed 53BP1-RIF1 may antagonize BRCA1 (not examined) and HR. A lot is known about these pathways, and it should be feasible to investigate them in much greater details to provide a better understanding of how viral integration occurs and how HHV-6A/B interferes with the DNA-damage response.

Other points:

3\. Fig. 3B: The exposure of the Alu-probed blot should be similar to the anti-TRF2 with (TTAGGG)3 probe to evaluate the data, in particular since nothing is provided about how linearity in the exposure interval is verified. One drawback of dot blots is the lack of size separation and thus an accumulated signal from everything that may bind the probe.

The HHV-6 DR6 probe apparently binds something in anti-Ig immunoprecipitated samples. If developed longer, it could look quite similar to anti-TRF2 IP. So how do the authors know that what is recognized in anti-TRF2 is not simply "non-specifically" precipitated DR or something completely different with cross-reactivity to the probe?

4\. Presentation of the kinetics for accumulation of viral DNA copies would make fig. 1D more convincing. What was the MOI for these infections?

5\. To appreciate the lack of colocalization of p41 with telomeres (fig.6G), the same 3D imaging as shown for fig. 6E should be provided.

Reviewer \#2: -Fig. 9b, lines 371-381: When using ddPCR, is it possible to specifically measure the "relative HHV-6A/B integration frequency" among a population of U2OS cells that contain either the HHV-6A/B genome integrated or within viral replication compartments? It's clear that TRF2 depletion leads to a reduction in the relative levels of HHV-6A/B viral genomes following infection of U2OS cells for one month, but is this a decrease in telomere integration or viral DNA replication? Providing quantitative analysis of FISH-IF (HHV-6A/B DNA and TTAGGG probe) on shSCR-U2OS and shTRF2-U2OS cells by counting the number of integration events within the total population of cells would be a potential means of addressing this question.

Reviewer \#3: Major issues (I used downloaded TIF versions of the figures.):

1\. An important, but readily addressable problem in the paper is that the figures and text do not explicitly state that the confocal microscopic images are of small numbers of nuclei, or of single nuclei. None of the images have scales. In the absence of DAPI staining (e.g., Fig. 1B) it would be helpful to provide outlines of nuclei. The DAPI images in Fig. 7 are too dim to be useful.

2\. The Fig. 4B y-axes should be something like: "Number of HHV-6A genomes/Number of host genomes". In Fig. 4C, the number of HHV-6B genomes per cell (\~80,000/cell) is extraordinarily high, especially since only 2 of the 5 nuclei shown in Fig. 1C appear to be infected with HHV-6B. Please double-check the math.

3\. In Fig. 5A, it would be helpful to show a merged image. It appears that the two images under IE2+ conditions are not presented at the same scale.

4\. The explanation of the Fig. 9 integration frequencies is inadequate. A brief description of the method is needed (not just the reference). It is not clear whether in this context, the assay measures integration frequency, as opposed to the frequency of 30-day survival of cells in which integration occurred.

5\. Why are there so many more IE2 spots in TRF1 and POT1 transfected cells than in non-transfected controls? IE2 is present in numerous donut-like structures in the transfected cells, but not in the non-transfected cells. How might this affect interpretations?

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: 1. Fig. 8: It needs to be clearly specified when the western blotting for shRNA is performed and when the infection experiment and the immunofluorescence staining is performed to make sure the expression on the Western blot is representative for the expression at the time of immunofluorescence analyses.

2\. The experimental conditions behind fig. 1E is not clearly described. Although some references to other papers are provided one should be able to understand the concepts from this paper alone. Thus, how was the data adjusted for the fact that uninfected cells keep dividing whereas infected cells stop dividing? How was telomeric repeats estimated?

3\. l.61: ...that play a role... -\> that are required

4\. l.315: "generally used" is an overstatement, as it seems only to refer to the authors themselves. Rephrase to "has been used"

5\. l.505: mead -\> mean

6\. l.526: "uninfected (white)" is "uninfeceted (blue)" on my computer??

7\. l.350: "colocalized perfectly with VRC, as evidenced by IE2 staining" It is not clear what qualifies it to be perfectly. Next, what is actually shown is colocalization to IE2. Therefore, it should be rephrased to "colocalized with IE2"

8\. l.358, l.359 and several other places: It seems that the designation VRC is an interpretation. Better to describe what is actually examined and observed. In fig. 1G HHV-6A delta(Imp TMR) induce pronounced telomeric signals One colocalize very well with IE2, the other not very well -- how should this be interpreted? And what does this mean for using IE2 staining as evidence of VRC?

9\. Fig. 6C does does not provide additional information to what is already stated in the text. Thus, it is not necessary.

10\. Fig. 8C: In my version of the paper, the mock cells and the HHV-6A cells -Dox (which are negative for antibody staining) have also much more dimly DAPI staining. Why is that?

(It may raise concerns about the compensation strategies during the collection of the immunofluorescent pictures.)

11\. Fig.4: In knock-down experiments it is concluded that depletion of TRF2 does not affect viral replication. In particular because of the lack of an effect of the depletion, it is not clear whether the remaining amount of TRF2 is sufficient to exert a given function.

Without this, fig. 4 is difficult to interpret and does not add much.

Reviewer \#2: Comments in this passage are focused primarily on the lack of clarity for some of the immunofluorescence images. It's unknown whether the lack of clarity is attributed to low image resolution or inefficient staining.

-Figs. 1b, 6a, 6b, 6e: Including a DAPI counterstain would more clearly define the location of the cell given that its unknown whether these images contain one cell or multiple cells in the field of view.

-Fig. 1b, lines 232-236: Given the low image resolution, it's difficult to differentiate between punctate (cellular) and "splotch" telomere signal. Would suggest providing a higher magnification of each example paired with localization of IE2 to more clearly convey this point.

-Fig. 6a: Surprising the telomere signal is very low (nearly absent) in mock group for Fig. 6a, but not in Fig. 6b. Furthermore, unable to observe "IE2 is also perfectly colocalized with VRC alongside p41" again due to low fluorescence intensity. May also want to include a comment in text describing the highlighted area containing the white box.

-Figs. 6b, 6f: How many cells were counted? Information is missing from the text.

-Figs. 7a, 7b: IE2 signal is very low in "HHV-6A; non-transfected" group. POT1 signal is also very low in the "POT1 transfected" group.

-Fig. 8d: In contrast to "HHV-6A (+) DOX" group, the "patchy" TTAGGG signal is absent from regions of IE2 in the "HHV-6A (-) DOX" group. Moreover, it appears that TTAGGG punctate foci are excluded from the "more pronounced VRC." This observation appears to be different from other figures in this manuscript.

-Lines 194-95, Fig. 3: Unclear why an input sample was taken prior to sonication. Input should have been from the same pool of chromatin that was used in the TRF2 and IgG ChIP. It's known that sonication aids in cell lysis during chromatin shearing, therefore the % input used in the figure does not accurately represent the efficiency of the ChIP.

-Line 199, Fig. 3: State the quantity (µg) of normal rabbit IgG used in the ChIP (not volume). If the same µg of antibody was not used for IgG and TRF2, authors would need to specify reason when representing background signal.

-Figs. 3c, 3e: If results are from 3 independent experiments, error bars and % input for IgG (background signal) is missing. Including IgG in this figure is critical given the noticeable IgG signal in HHV-6A and HHV-6B infected cells (see Figs. 3b and 3d).

-Line 206, Fig. 2c: Why were different amounts of MBP (25 ng) and MBP-TRF2 (50 ng) used in the in vitro binding assay? Puzzling given that MBP alone serves as a control for the nonspecific binding to HHV-6A DNA.

-Line 295-296: Consider including RNAPII ChIP data into Fig. 3 or supplementary information rather than stating data is "not shown."

-Fig. 8a: Would suggest re-running this western to achieve individual clean bands with densitometry analysis.

-Given the similar roles of TRF1 and TRF2 in the maintenance of telomere stability, may want to include a very brief comment why TRF2 and not TRF1 was the primary focus? Could there be redundancy between both TRF1 and TRF2, such that depleting both proteins or TRF1 alone leads to a greater decrease in viral integration? This is purely speculative...experiments are not necessary.

Reviewer \#3: Suggested edits or points needing clarifications:

1E -- y-axis needs a label -- is this intensity or copy number

Fig. 2. Panels A and B should have competitors expressed in pmoles, as is done for Panel C.

In Panel A, what are the units for the 10, 100, and 1000 telo and non-telo numbers

In Panel C, what are the molar ratios between the target (25 ng of genomes) and the competitors?

Fig. 4A. It is hard to tell whether the bands seen in the +Dox lane are background expression or leakage from the adjacent lane. If it is the latter, the authors' case would be stronger.

Silencing TRF2 seems to have a small but fairly consistent positive effect on HHV-6A genome replication.

Fig. 6A. No scales are provided. Are these high-magnification images of single nuclei? State that the boxes are the region shown in the 3D representation. What do you make of the IE rings (more common with the deletion mutant)? The difference in localization relative to the TTAGGG probe should be mentioned.

In 6C, it is easy to see the relationship of the patterns for the TTAGGG, IE2, Merged, and XYZ panels, because they are presented in the same relative positions in all four panels. For the IE2 deletion data in panel 6E, the XYZ panel is rotated relative to the others. I do not see how the XYZ panel in the empty vector row relates to the first three panels. Related to this, I could only figure out how the deletion 3D image relates to the rest in its row. What is the scale? What is the definition of "at telomere"? It would be helpful to show at least two images of the 3D reconstructions: one in an orientation that correspoinds to the XYZ panel (which should correspond to the others in that row), and one rotated to make whatever other point is intended. Movies that show the reconstruction rotating in space would be helpful.

The Fig. 6G legend text should be modified to say "Lack of colocalization between HHV-6A p41 and telomeres in uninfected cells."

Fig. 7A and 7B. In the top rows, why are there so many more IE2+ spots in the 3D rendering?

Fig. 8B. Why are the TTAGGG signals so much more pixelated than the other signals (looking at the high resolution TIFF images)?

Why is the IE2 staining in Fig. 8 panel B so much more diffuse than in Panels C and D. This is not an image size or resolution issue.

Fig. 9B y-axis: "frequency"

line 505. "mean absorbance"
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Dear Dr. Flamand,

Thank you very much for submitting your manuscript \"Role for the shelterin protein TRF2 in human herpesvirus 6A/B chromosomal integration\" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

The Reviewers have given this paper very careful and thorough consideration. They find the work an interesting and important contribution to understanding the roles of TRF2 in HHV-6 chromosomal integration. Reviewer 1 suggests correction of what is essentially a typo. Reviewer 2 has a handful of reasonable questions and suggestions related to figures and the image analysis; I would like to see a revision that addresses their concerns.
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\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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The Reviewers have given this paper very careful and thorough consideration. They find the work an interesting and important contribution to understanding the roles of TRF2 in HHV-6 chromosomal integration. Reviewer 1 suggests correction of what is essentially a typo. Reviewer 2 has a handful of reasonable questions and suggestions related to figures and the image analysis; I would like to see a revision that addresses their concerns.

Reviewer Comments (if any, and for reference):

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: HHV-6A/B can integrate in host cell chromosomes, but the mechanism is unknown. The revised version of this paper has been significantly improved by addressing some critical issues and by presenting the data in a more focused way.

The authors describe that productive HHV-6A/B infections increase viral telomeric sequences; shelterin proteins are recruited to the viral replication compartment; shelterin protein TRF2 binds to viral telomeric repeats; TRF2 knockdown reduces localization of viral IE2 to cellular telomeres and reduces frequency of viral integration. They conclude that TRF2 has a role in HHV-6/B integration.

Although the paper does not provide a mechanism for the chromosomal integration process, it does provide a first step in the understanding of this apparently unique feature of HHV-6A/B among the human herpesviruses.

Reviewer \#2: With this current submission the authors have addressed a number of questions that were brought up during the course of review. Comments are provided to aid in the clarity in some of the results and conclusions.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: (No Response)

Reviewer \#2: -Fig 1b, lines 247-249: Based on the images provided it appears that strong IE2 signal is excluded from the p41 signal, hence the two proteins are adjacent rather than colocalizing. What is the Mander's colocalization coefficient for p41 and IE2? This is important to establish given the use of IE2 as a marker for viral replication compartment in all subsequent figures. Also, poor image resolution (pixilated) may be a culprit for the lack in clarity.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: l.35: "integration frequency" is mentioned twice in the same sentence. Please correct.

Reviewer \#2: -Fig 1b, lines 251-253: Based on very low signal "telomeric probe resulted in the detection of many discrete punctate telomeric signal" is not apparent in Fig 1b, but is in Fig 1c. Again, this is the same general issue as brought up in the previous review of low signal or low image resolution.

-Fig 1g, lines 275-284: In this figure it is obvious that HHV-6A and HHV-6AdeltaimpTMR have an IE2 signal that localizes with telomere. However, without providing a positive IE2 infected cell for HHV-6AdeltaTMR its difficult to conclude "the viral genome were responsible for increased telomeric signals observed." To make this conclusion an HHV-6AdeltaTMR infected cell with positive IE2 signal would need to be shown with telomere signal that does not colocalize. Poor image resolution maybe a culprit again, but the data presented should be clear.

-Fig 4a, lines 335-336: Provide the Mander's colocalization coefficient to conclude "TRF2 appeared to colocalize with IE2."

-Fig 5a, lines 564-566: Authors need to define the difference between patchy and punctate IE2 signal with regards to VRC. Is it possible to conclude that "infected cells that do not actively replicate viral DNA with TRF2 and IE2 colocalization" when there are no viral DNA FISH controls to support these conclusions of which IE2 staining pattern (patchy vs punctate) represents VRCs?

-Fig 5b, lines 346-351: The % colocalization of punctate IE2 with TRF2 was provided in Fig 5a, but this information is missing for IE2 and TRF1.

-Fig 6d, lines 363-365: The p41 signal appears to be localized as a concentric ring around the nucleus and not "p41 exhibit a diffuse nuclear distribution."

-Lines 589-590, Fig 7c: Describe how the percent of IE2 positive cells were "estimated" as opposed to providing an absolute count instead?
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [[https://pacev2.apexcovantage.com](https://pacev2.apexcovantage.com/)]{.ul}. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at [<figures@plos.org>]{.ul}.

[Data Requirements:]{.ul}

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

[Reproducibility:]{.ul}

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [[http://journals.plos.org/plospathogens/s/submission-guidelines\#loc-materials-and-methods](http://journals.plos.org/plospathogens/s/submission-guidelines)]{.ul}
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Dear Dr. Flamand,

Thank you for your positive responses to the reviewers throughout this process. We are very pleased to inform you that your manuscript \'Role for the shelterin protein TRF2 in human herpesvirus 6A/B chromosomal integration\' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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Philip E. Pellett, PhD
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Dear Dr. Flamand,

We are delighted to inform you that your manuscript, \"Role for the shelterin protein TRF2 in human herpesvirus 6A/B chromosomal integration,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.
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